New hope for lymphoma patients: drug combo plus optional transplant
NCT ID NCT07199296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs (orelabrutinib and rituximab) in people newly diagnosed with a type of blood cancer called mantle cell lymphoma that is not high-risk. Some participants may also receive a stem cell transplant using their own cells. The goal is to see how well the treatment shrinks or eliminates the cancer and how safe it is. About 45 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital
RECRUITINGShanghai, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a chemo-free cocktail tame mantle cell lymphoma?
- Engineered immune cells take on tough lymphomas
- New drug duo aims to outsmart resistant lymphoma
- New combo pill attack aims to control blood cancers
- New CAR-T therapy aims to stop High-Risk lymphoma early
- New drug takes aim at Hard-to-Treat blood cancers